[PRESS RELEASE] – EDMONTON, Alberta, Feb. 20, 2025 – Aurora Cannabis Inc., the Canadian-based leading global medical cannabis company, announced the company's extended pastille offerings in Australia. This expansion marks another meaningful step in Aurora's deep commitment to offering patients a diverse range of high-quality, premium medical cannabis products to meet their various needs and interests.
"Expanding our portfolio of medical cannabis pastilles in Australia demonstrates our understanding of market demand and is another example of our ability to bring high-quality product to this key market as patient interest increases," said Andre Jerome, executive vice president of Global Business Development at Aurora. "In this rapidly expanding market, we're leveraging our unique capabilities, including global manufacturing and excellence in navigating regulatory frameworks that define Aurora's leadership."
Medical cannabis pastilles offer several key benefits, including easy oral intake. The prolonged effects provide long-lasting and extended relief after digestion. Pastilles also come in an accessible format that is discrete, portable, and convenient.
The pastilles that are now available in Australia include:
- Aurora Pastilles - 10mg THC Pomegranate Berry (30 pack)
- Aurora Pastilles - 10:10 Balanced Pineapple (30 pack)
- Aurora Pastilles - 25mg CBD Acai Berry (30 pack)
Aurora maintains its position as the largest global medical cannabis company operating in nationally legal markets. The company has a robust innovation pipeline planned for global introduction over the coming months, bringing variety and new options to patients.
